STOCK TITAN

Health Catalyst (HCAT) SEC Filings, Sep 1-11, 2026

HCAT NASDAQ

Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.

The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.

Rhea-AI Summary

Health Catalyst, Inc. (HCAT) reported that CEO and director Albert Benjamin had 35,244 shares of common stock disposed of on September 10, 2026 at $1.6747 per share to satisfy tax withholding obligations related to vesting Restricted Stock Units. After this tax-withholding transaction, he directly holds 1,388,406 shares of common stock. The sale was executed as a mandatory "sell to cover" under the company’s equity incentive plans and is described as not being a discretionary trade.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
insider
-
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) is the issuer of common stock covered by a notice filed on behalf of Benjamin Albert under Rule 144. The notice relates to the proposed sale of 35,244 shares of common stock through Morgan Stanley Smith Barney LLC, to be sold on or about September 10, 2026 on NASDAQ.

The filing also lists prior sales of restricted stock by Benjamin Albert during the preceding three months, and states that Health Catalyst, Inc. had 75,256,381 shares of common stock outstanding as of the time indicated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
other
-
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) is the subject of an amended Schedule 13D filing by investment entities affiliated with Palogic, which report beneficial ownership of 5,374,949 shares of common stock, representing 7.1% of the company’s outstanding shares as of July 31, 2026.

The Palogic group—Palogic Value Fund, Palogic Value Management, Palogic Capital Management, and Ryan L. Vardeman—acquired these shares for an aggregate of approximately $11,790,874 in open‑market transactions. On September 4, 2026, Palogic Value Management sent a letter to Health Catalyst’s board applauding the VitalWare sale and requesting a clearer forward‑looking business plan, more detailed and separated R&D cost disclosure, enhanced revenue and business-metric disclosure, and discussion of capital allocation and the path to profitable growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
ownership
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) announced a leadership transition, appointing Simeon Kohl as Chief Executive Officer, President, principal executive officer and principal operating officer, and as a Class III director effective September 14, 2026, succeeding Ben Albert. Albert will resign as CEO, President and director effective September 13, 2026 and become Chief Business Officer.

Kohl’s offer letter provides a $600,000 base salary, annual bonus target equal to 100% of base salary, Tier 1 participation in the Executive Severance Plan, and a planned grant of 2,747,385 RSUs, including 915,975 RSUs vesting on September 4, 2027 and the remainder in eight quarterly installments. The Board also adopted a new 2026 Employment Inducement Incentive Plan, reserving 2,747,385 shares for awards to new or returning employees under Nasdaq’s inducement award rules. The press release highlights Kohl’s prior leadership of Performant Healthcare through its sale to Machinify for approximately $670 million and notes that Health Catalyst has documented $2.8 billion in outcomes and previously used the Vitalware divestiture to retire an approximately $160 million credit facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
current report
-
Rhea-AI Summary

Health Catalyst, Inc. (symbol: HCAT) is the issuer of record for a Form 4 filing submitted to the SEC. Larson-Green Julie reported acquisition or exercise transactions in this Form 4 filing.

Health Catalyst, Inc. (HCAT) reported that director Julie Larson-Green received an award of 9,766 restricted stock units (RSUs) of common stock under the company’s 2019 Stock Option and Incentive Plan. Each RSU represents one share of common stock, and 100% of the RSUs vested on September 1, 2026, bringing her direct holdings to 185,101 shares. The award was granted at no cash purchase price, and no Rule 10b5-1 trading plan is reported for this transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
insider
-
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) reported that Chief Financial Officer Jason Alger had 17,973 shares of common stock disposed of on September 1, 2026 to cover tax withholding obligations tied to vesting Restricted Stock Units. The transaction, at $1.7036 per share, was a mandated sell-to-cover and not a discretionary trade, leaving him with 704,867 shares held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
insider
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) director and CEO Albert Benjamin reported a Form 4 transaction related to equity compensation. On September 1, 2026, he disposed of 321 shares of common stock at $1.7036 per share to cover tax withholding obligations arising from vesting of Restricted Stock Units, a sale mandated under the company’s equity incentive plans rather than a discretionary trade. Following this tax-withholding transaction, he directly holds 1,423,650 shares of common stock, and no Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
insider
-
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) reported that its General Counsel, Benjamin Landry, had 13,167 shares of common stock disposed of on September 1, 2026 at $1.7036 per share to satisfy tax withholding obligations from vesting Restricted Stock Units. The filing states this mandated "sell to cover" transaction was not a discretionary trade and left him with 351,372 shares held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
insider
-
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) officer Benjamin Albert filed a Form 144 indicating a proposed sale of 321 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on or about 09/01/2026 under Rule 144. The securities are restricted stock originally acquired as compensation. Over the prior three months, Albert reported Rule 144 sales of restricted stock on 06/01/2026 and 06/10/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
other
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) has a Form 144 filing indicating that officer Jason Alger plans to sell up to 17,973 shares of common stock of Health Catalyst through Morgan Stanley Smith Barney LLC under Rule 144, with an intended sale date of September 1, 2026.

The shares are described as Restricted Stock acquired as compensation75,256,381 as of September 1, 2026; this is a baseline figure, not the amount being sold. Over the prior three months, Alger reported selling 18,804 restricted shares for an aggregate value of $25,765.24.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
other

FAQ

How many Health Catalyst (HCAT) SEC filings are available on StockTitan?

StockTitan tracks 127 SEC filings for Health Catalyst (HCAT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Health Catalyst (HCAT)?

The most recent SEC filing for Health Catalyst (HCAT) was filed on November 13, 2026.